|Application:||Gene expression microarray analysis|
|Number of samples:||112|
|Release date:||Oct 29 2014|
|Last update date:||Apr 20 2018|
|Diseases:||Arthritis, Rheumatoid, Neoplasms, Psoriasis, Arthritis, Psoriatic|
|Dataset link||Gene expression of CD14+ cells from RA, PsA and PsO patients with Infliximab treatment|
Between April 2007 and June 2009, 31 patients with active RA, PsA and Ps who were naÃ¯ve to anti-TNF agents, were recruited from the Faculty Rheumatology Clinics at the University of Rochester Medical Center after informed, written consent was obtained in a protocol approved by the Research Subjects Review Board at the University of Rochester Medical Center. Of the 31 subjects, 9 had active RA and 12 had PsA despite treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs). Also, 10 patients with extensive Ps (>5% BSA) documented by a dermatologist, were enrolled and they were examined by a rheumatologist to exclude the presence of inflammatory arthritis. Nineteen healthy controls were also recruited.
Citations per year